In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

Science
R YarchoanS Broder

Abstract

The purine analog 2',3'-dideoxyinosine (ddI), which has anti-retroviral activity in vitro was administered for up to 42 weeks to 26 patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex (ARC). Ten of these individuals were AZT-intolerant. Eight dose regimens were studied. The drug was orally bioavailable and penetrated into the cerebrospinal fluid (CSF). Comparatively little evidence of an effect against human immunodeficiency virus (HIV) was seen at the lowest four doses. However, patients in the four highest dose groups (ddI at 1.6 milligrams per kilogram intravenously and then greater than or equal to 3.2 milligrams per kilogram orally at least every 12 hours or higher) had increases in their circulating CD4+ T cells (P less than 0.0005), increased CD4/CD8 T cell ratios (P less than 0.01), and, where evaluable, more than an 80% decrease in serum HIV p24 antigen (P less than 0.05). The patients also had evidence of improved immunologic function, had reduced viremic symptomatology, and gained a mean of 1.6 kilogram with these comparatively infrequent dosing schedules (every 8 or 12 hours). The most notable adverse effects directly attributable to ddI administration at the doses used in this stu...Continue Reading

References

Feb 4, 1987·Nature·H Mitsuya, S Broder
Dec 15, 1988·The New England Journal of Medicine·F A SchmittJ L Drucker

❮ Previous
Next ❯

Citations

Apr 26, 1991·Pharmaceutisch Weekblad. Scientific Edition·E H Wiltink, R Janknegt
Oct 16, 1992·Pharmaceutisch Weekblad. Scientific Edition·R M FranssenJ H Beijnen
Jan 1, 1990·Biotherapy·S E Krown
Jul 13, 2006·Archives of Pharmacal Research·Jin Woo Kim, Joon Hee Hong
Feb 1, 1997·Archives of Pharmacal Research·E R WooH Park
Oct 17, 2003·Archives of Pharmacal Research·Eun Yee KwakBo Gil Choi
Mar 23, 1991·Lancet·J C PonsJ F Delfraissy
Dec 1, 1990·Antiviral Research·W KreisP S Sarin
Sep 1, 1990·Immunology Today·R YarchoanS Broder
Jan 1, 1991·International Journal of Immunopharmacology·M I LusterJ E Tomaszewski
Aug 1, 1991·Current Opinion in Immunology·A J Pinching
Jun 11, 2005·Bioorganic & Medicinal Chemistry·Junbiao ChangRongfeng Chen
Nov 4, 1989·Lancet
Jun 6, 2000·Advanced Drug Delivery Reviews·L I Wiebe, E E Knaus
Jun 6, 2000·Advanced Drug Delivery Reviews·M B YatvinM A Shenoy
Sep 30, 2000·Bioorganic & Medicinal Chemistry Letters·N Nguyen-BaB Zacharie
Jan 30, 2002·Bioorganic & Medicinal Chemistry·Ke LiMichael B Doughty
Jun 9, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·J G García-Lerma, W Heneine
Sep 14, 1989·The New England Journal of Medicine·R YarchoanS Broder
Nov 8, 1990·The New England Journal of Medicine·D P ByarS Lagakos
Jan 17, 1991·The New England Journal of Medicine·K M ButlerH Moss
Aug 27, 1992·The New England Journal of Medicine·J E Groopman, J M Molina
Jun 10, 1993·The New England Journal of Medicine·M S Hirsch, R T D'Aquila

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.